1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Ypsomed Holding AG

Ypsomed Holding AG

418.20
EUR
-1.40
(-0.33%)
3.99BMarket Cap
Nov 11Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
21.83
24.21
26.61
30.79
36.92
35.89
31.19
31.91
36.76
37.07
40.18
54.87
53.72
- -
Basic EPS, GAAP
1.08
1.53
2.83
3.66
4.12
4.76
0.93
0.46
1.83
3.82
5.74
6.41
16.31
- -
Free Cash Flow per Basic Share
0.84
0.86
3.2
2.92
-1.09
-5.47
-5.51
-3.22
-3.3
-2.95
-2.35
-9.45
-1.2
- -
Dividend per Share
0.2
0.3
0.6
1
1.3
1.4
0.55
0.2
1.16
0.61
1.3
2
2.21
- -
Book Value per Share
18.03
19
21.17
23.84
27.02
29.96
29.87
31.18
30.94
41.2
45.26
49.81
56.91
56.91
Tangible Book Value per Share
13.19
13.55
15.4
18.03
20.92
23.52
21.76
18.5
15.9
24.22
24.63
27.06
47.35
47.35
Basic Weighted Avg Shares
13
13
13
13
13
13
13
13
13
13
14
14
14
14
Sales/Revenue/Turnover
276
307
337
390
466
454
394
404
465
497
548
749
731
- -
Operating Margin (%)
5.66
9.31
13.19
14.2
13.1
16.16
2.46
2.3
6.15
12.18
15.72
15.07
33.66
- -
Depreciation Expense
25
26
27
31
34
45
53
56
68
79
75
80
82
- -
Net Income, GAAP
14
19
36
46
52
60
12
6
23
51
78
88
222
- -
Effective Tax Rate (%)
10.73
18.28
17.1
16.51
15.97
13.94
- -
4.94
9.53
9.47
4.28
16.11
7.9
- -
Profit Margin (%)
4.93
6.33
10.63
11.87
11.17
13.25
2.98
1.44
4.97
10.31
14.29
11.68
30.36
- -
Working Capital
12
23
43
72
76
-9
-86
-87
-44
-51
-102
-69
21
21
LT Debt
20
15
10
10
10
10
10
33
110
- -
- -
100
112
112
Total Equity
228
241
268
302
342
379
378
395
393
562
618
680
748
748
Return on Invested Capital (%)
4.54
7.47
11.74
14.05
13.69
13.8
- -
1.46
4.07
7.95
10.31
9.73
21.53
- -
Return on Capital (%)
4.75
6.46
11.62
14.3
14.16
13.46
- -
1.26
3.93
7.71
10.42
9.69
21.88
- -
Return on Common Equity (%)
6.11
8.27
14.09
16.24
16.18
16.7
3.1
1.5
5.86
10.74
13.28
13.49
31.09
- -

Capital Structure

CHF

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
267
- -
149
LT Borrowings
100
- -
112
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
13
13
Market Capitalization
- -
3,989
3,683

Working Capital

CHF

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
427
370
321
Cash, Cash Equivalents & STI
36
36
29
Accounts Receivable, Net
174
142
187
Inventories
86
69
61
Total Current Liabilities
496
252
301
Payables & Accruals
- -
- -
- -
ST Debt
267
- -
149
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.36%
14.5%
10.07%
Free Cash Flow
40.66%
38.57%
-87.33%
Net Income, GAAP
56.39%
127.53%
153.62%
Sales/Revenue/Turnover
8.85%
13.32%
-2.39%
Total Cash Common Dividend
59.79%
123.62%
9.97%

Semi-annual Revenue

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
548
2025
- -
- -
749
2026
- -
- -
731

Semi-annual Earnings Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5.74
2025
- -
- -
6.41
2026
- -
- -
16.31

Semi-annual Dividends Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.3
2025
- -
- -
2
2026
- -
- -
2.21

Company Description

Company Profile APIChatGPT
CEO
Simon Michel
Full Time Employees
2,025
Sector
Health technology
Industry
Medical specialties
Address
Brunnmattstrasse 6 Burgdorf BE Switzerland 3401
IPO Date
Sep 22, 2004
Website
ypsomed.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Ypsomed Holding AG develops and manufactures customized injection and infusion systems for self-administration of liquid medications, serving as a key partner to pharmaceutical and biotech companies worldwide. Founded in 1984 and headquartered in Burgdorf, Switzerland, the company operates through a global network including production sites in Switzerland, Germany and China; it focuses on the Delivery Systems segment, providing precision-engineered drug delivery platforms such as disposable and reusable pen injectors including the YpsoMate platform, autoinjectors for high-viscosity biologics, on-body wearable devices, and related contract development and manufacturing services (CDMO). Ypsomed markets these solutions primarily through pharmaceutical partnerships targeting therapies for diabetes, autoimmune diseases, infertility, growth disorders and other chronic conditions, with geographic operations spanning Switzerland, Europe, North America and international markets. In recent strategic shifts, Ypsomed sold its Diabetes Care business, including Ypsomed Diabetes Care AG and patch pump activities such as the mylife YpsoPump and mylife Loop, to TecMed AG for up to CHF 420 million in July 2025, enabling a pivot to a pure-play injection systems provider and funding expansions like new production halls in Solothurn and a potential U.S. manufacturing site by 2027. The company further divested its precision turned parts subsidiary Ypsotec AG to Callista Asset Management 32 GmbH on 31 October 2025 to sharpen focus on core medtech competencies and enhance financial flexibility for growth initiatives. These moves follow a 2024 strategic review and build on partnerships such as the October 2024 collaboration with BD to advance self-injection systems for high-viscosity biologics, alongside robust revenue growth in autoinjectors driven by GLP-1 therapies.